FGP
TGTX icon

Freestone Grove Partners’s TG Therapeutics TGTX Stock Holding History

Freestone Grove Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,379
Closed -$810K – 1320
2026
Q1 		$810K Buy
24,379
+9,633
+65% +$287K 0.01% 514
2025
Q4 		$440K Buy
+14,746
New +$482K ﹤0.01% 593
2025
Q1 		– Sell
-7,433
Closed -$224K – 783
2024
Q4 		$224K Buy
+7,433
New +$213K ﹤0.01% 518

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Freestone Grove Partners's TGTX Position: Q2 2026 in Review

Freestone Grove Partners sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 24,379 shares — an estimated $810K sold.

Freestone Grove Partners first reported a position in TGTX in Q4 2024 and held it in 3 quarters. The position peaked at $810K in Q1 2026. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Freestone Grove Partners reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 24,379 TG Therapeutics shares in Q2 2026, an estimated $810K.
  • Freestone Grove Partners first reported a position in TG Therapeutics in Q4 2024 and held it in 3 quarters.
  • Freestone Grove Partners's TG Therapeutics position peaked at $810K in Q1 2026.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.